Patricia Bradford Biography and Net Worth



Patricia A. Bradford has served as a member of the Board since 2022. Ms. Bradford served as Senior Vice President Global Human Resources at Unisys Corporation, a global information technology solutions company, where her total service at Unisys spanned from 1982 until her retirement in 2014. In her role at Unisys, Ms. Bradford strategically led all global human resource programs and initiatives, including talent management, at multiple levels of the organization overseeing an HR team of 200+ in 42 countries. Ms. Bradford’s roles at Unisys progressively included all areas of human resources, including an overseas assignment at the Unisys European headquarters where she provided human resources leadership to the region. She as well participated as a member of the Unisys US Pension Investment Committee which reviewed the investment portfolio and appropriate investment strategies quarterly. Prior to Unisys, Ms. Bradford was employed by Deloitte, an audit, consulting, tax, and advisory services firm, from 1977 to 1982. There she was responsible for preparing cash flow reports, balance sheets and income statements as well as specializing in Expatriate tax returns. Since 2014, Ms. Bradford has maintained a consulting practice focused on individual coaching for senior executives and high potential employees recommended by management. Ms. Bradford received a B.S. degree with an emphasis in accounting and statistics from Walsh College and is a Certified Public Accountant.

What is Patricia A. Bradford's net worth?

The estimated net worth of Patricia A. Bradford is at least $63.64 thousand as of September 24th, 2026. Ms. Bradford owns 64,151 shares of Phio Pharmaceuticals stock worth more than $63,638 as of October 6th. This net worth evaluation does not reflect any other assets that Ms. Bradford may own. Learn More about Patricia A. Bradford's net worth.

How do I contact Patricia A. Bradford?

The corporate mailing address for Ms. Bradford and other Phio Pharmaceuticals executives is 411 Swedeland Road, Suite 23-1080, King OF Prussia, PA, 19406. Phio Pharmaceuticals can also be reached via phone at (508) 767-3861 and via email at [email protected]. Learn More on Patricia A. Bradford's contact information.

Has Patricia A. Bradford been buying or selling shares of Phio Pharmaceuticals?

Patricia A. Bradford has not been actively trading shares of Phio Pharmaceuticals during the past quarter. Most recently, on Thursday, September 24th, Patricia A. Bradford bought 6,500 shares of Phio Pharmaceuticals stock. The stock was acquired at an average cost of $1.01 per share, with a total value of $6,565.00. Following the completion of the transaction, the director now directly owns 64,151 shares of the company's stock, valued at $64,792.51. Learn More on Patricia A. Bradford's trading history.

Who are Phio Pharmaceuticals' active insiders?

Phio Pharmaceuticals' insider roster includes Robert Bitterman (President & Chief Executive Officer), Patricia Bradford (Director), and Gerrit Dispersyn (CEO). Learn More on Phio Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Phio Pharmaceuticals?

During the last year, Phio Pharmaceuticals insiders bought shares 8 times. They purchased a total of 53,500 shares worth more than $57,925.00. The most recent insider tranaction occured on September, 28th when Director Ronald Todd Plott bought 5,000 shares worth more than $5,150.00. Insiders at Phio Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Phio Pharmaceuticals.

Information on this page was last updated on 9/28/2026.

Patricia A. Bradford Insider Trading History at Phio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/24/2026Buy6,500$1.01$6,565.0064,151View SEC Filing Icon  
See Full Table

Patricia A. Bradford Buying and Selling Activity at Phio Pharmaceuticals

This chart shows Patricia A. Bradford's buying and selling at Phio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phio Pharmaceuticals Company Overview

Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More

Today's Range

Now: $0.99
Low: $0.97
High: $1.02

50 Day Range

MA: $1.06
Low: $0.98
High: $1.21

2 Week Range

Now: $0.99
Low: $0.81
High: $4.19

Volume

131,685 shs

Average Volume

1,478,603 shs

Market Capitalization

$11.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84